Skip to content
Inciteful Med

Understanding Multiple Myeloma: An Introduction

Last updated:

Multiple Myeloma is a cancer of plasma cells in the bone marrow that produce abnormal M-proteins. It often progresses from a benign stage called MGUS to active disease defined by the CRAB criteria (calcium, kidney, anemia, bone issues). Though incurable, modern treatments make it a manageable chronic condition for many.

Key Takeaways

  • • Multiple Myeloma is a cancer of plasma cells that produce abnormal M-proteins instead of healthy antibodies.
  • • The disease often evolves through asymptomatic stages called MGUS and Smoldering Myeloma before becoming active.
  • • Active disease is identified by the CRAB criteria: Calcium elevation, Renal failure, Anemia, and Bone damage.
  • • African Americans are two to three times more likely to develop this condition than white individuals.
  • • New treatments have significantly improved survival rates, turning the disease into a chronic, manageable condition for many.

If you or a loved one has recently been diagnosed with Multiple Myeloma, it is natural to feel overwhelmed. However, it is important to know that the landscape of this disease has changed dramatically in the last two decades. While it is currently considered incurable, it has become a highly treatable condition that many people manage for years, much like a chronic illness [1][2].

What is Multiple Myeloma?

Multiple Myeloma is a type of blood cancer that begins in your plasma cells, which are found in the bone marrow (the soft tissue inside your bones) [3][4].

In a healthy body, plasma cells are part of the immune system and produce antibodies—proteins that help fight infections [5]. In someone with Multiple Myeloma, these plasma cells become cancerous and multiply uncontrollably. Instead of making helpful antibodies, they produce abnormal proteins called M-proteins (or monoclonal proteins) [5][6]. These “bad” proteins do not help fight infection and can build up in the blood or urine, potentially damaging the kidneys and other organs [5][7].

The word “Multiple” refers to the fact that these cancerous cells typically appear in many different locations throughout the bone marrow, rather than in just one spot [5][8]. It is not skin cancer (melanoma).

The Spectrum: From “Sleeping” to “Active”

Multiple Myeloma often develops slowly through three distinct stages. Doctors sometimes describe these as “sleeping” or “waking” versions of the disease [3][9]:

  1. MGUS (Monoclonal Gammopathy of Undetermined Significance): This is a benign, “sleeping” condition. The abnormal protein is present, but there are very few cancerous cells (<10%<10\%) and no symptoms [10][11]. The risk of this turning into cancer is low (1% per year) [10].
  2. Smoldering Multiple Myeloma (SMM): This is an intermediate stage where the “disease” is starting to wake up. There are more cancerous cells (10−60%10-60\%), but still no organ damage [10][11]. Some people stay here for years without needing treatment [12].
  3. Active Multiple Myeloma: This is the “awake” stage where the cancer is causing symptoms or damage. Doctors diagnose this using the CRAB criteria (Calcium, Renal, Anemia, Bone) [5][6].

Who is at Risk?

Multiple Myeloma is primarily a disease of older age. The majority of people (85%) are diagnosed after age 65 [13][14].

There is a significant racial disparity: African Americans are two to three times more likely to develop Multiple Myeloma than white individuals [15][16].

Reasons for Hope

If you are looking at survival statistics online, please be aware that they often reflect older data.

  • Survival is Rising: While older data (2010-2016) showed a 5-year survival of around 53%, recent data suggests this has risen to nearly 60%, and for standard-risk patients treated with modern therapies, it can be significantly higher [17][18].
  • A “Chronic” Disease: For many, Multiple Myeloma is now managed with long-term “continuous therapy,” similar to diabetes [2][19].
  • New Tools: A wide array of modern treatments—including immunotherapies and targeted drugs—has expanded the options for keeping the disease in check for long periods [1][20].

Frequently Asked Questions

What is Multiple Myeloma?
Multiple Myeloma is a cancer of the plasma cells found in your bone marrow. In a healthy body, these cells fight infection, but in Myeloma, they multiply uncontrollably and produce abnormal M-proteins that can damage the kidneys and bones.
What is the difference between MGUS, Smoldering, and Active Myeloma?
MGUS is a benign, 'sleeping' stage with no symptoms and low risk. Smoldering Myeloma is an intermediate stage with more abnormal cells but no organ damage. Active Myeloma causes symptoms or organ damage (CRAB criteria) and requires treatment.
What are the symptoms of active Multiple Myeloma?
Doctors look for the 'CRAB' criteria to diagnose active disease: increased Calcium levels, Renal (kidney) dysfunction, Anemia (low red blood cells), and Bone abnormalities like lesions or pain.
Is Multiple Myeloma curable?
While currently considered incurable, Multiple Myeloma is highly treatable. With modern immunotherapies and targeted drugs, many patients manage the disease for years, similar to a chronic illness like diabetes.
Who is at risk for Multiple Myeloma?
The disease primarily affects people over age 65. There is also a significant racial disparity, with African Americans being two to three times more likely to develop Multiple Myeloma than white individuals.

Questions for Your Doctor

  • • What were my specific 'M-spike' and 'bone marrow plasma cell percentage' results?
  • • Do I have any 'high-risk' markers, such as del(17p), and how will that affect my treatment plan?
  • • Am I currently in the 'MGUS,' 'Smoldering,' or 'Active' stage of the disease?
  • • Have you checked for bone lesions using an MRI or PET-CT, even if I don't feel any bone pain?
  • • How will we monitor my kidney function and calcium levels during treatment?
  • • Given the recent advancements, what is the outlook for someone with my specific profile?

Questions for You

  • • What symptoms, such as bone pain or fatigue, first brought me to the doctor?
  • • Do I have a family history of blood cancers (even though this is rarely hereditary)?
  • • What are my primary goals for treatment (e.g., travel, working, attending a family event)?
  • • Am I ready to advocate for myself by asking questions when I don't understand something?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    New therapies in multiple myeloma: benefits and limitations.

    Jurczyszyn A, Bator M, Vesole DH, et al.

    Polish archives of internal medicine 2025; (135(4)) doi:10.20452/pamw.16994.

    PMID: 40231696
  2. 2

    Pathogenesis and treatment of multiple myeloma bone disease.

    Hiasa M, Harada T, Tanaka E, Abe M

    The Japanese dental science review 2021; (57()):164-173 doi:10.1016/j.jdsr.2021.08.006.

    PMID: 34611468
  3. 3

    18F-FDG PET/CT in monoclonal plasma cell disorders.

    Paschali A

    Hellenic journal of nuclear medicine 2023; (26 Suppl()):38-41.

    PMID: 37658561
  4. 4

    A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.

    Sabobeh T, Brugioni EK, Masoud A, et al.

    Cureus 2021; (13(2)):e13293 doi:10.7759/cureus.13293.

    PMID: 33728224
  5. 5

    Cutaneous Multiple Myeloma.

    Miriyala LKV, Avasthi D

    Cureus 2021; (13(9)):e17779 doi:10.7759/cureus.17779.

    PMID: 34659990
  6. 6

    Light chain multiple myeloma: an evaluation of its biochemical investigations.

    Zahari Sham SY, C Thambiah S, Samsudin IN, Lim SM

    The Malaysian journal of pathology 2017; (39(3)):311-315.

    PMID: 29279596
  7. 7

    [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].

    Gödecke V, Schmidt JJ, Bräsen JH, et al.

    Der Internist 2019; (60(1)):10-22 doi:10.1007/s00108-018-0538-7.

    PMID: 30635666
  8. 8

    Rare Pedal Manifestation of Diffuse Multiple Myeloma Lesions.

    Saviet BM, Marcoux JT, Narayanasami U

    The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons 2017; (56(2)):357-361 doi:10.1053/j.jfas.2016.11.020.

    PMID: 28231967
  9. 9

    A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.

    Awada H, Thapa B, Awada H, et al.

    Cells 2021; (10(8)) doi:10.3390/cells10081961.

    PMID: 34440730
  10. 10

    MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.

    Mateos MV, Landgren O

    Cancer treatment and research 2016; (169()):3-12 doi:10.1007/978-3-319-40320-5_1.

    PMID: 27696254
  11. 11

    [Expert consensus on the comprehensive management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma in China (2025)].

    ,

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(3)):198-208 doi:10.3760/cma.j.cn121090-20241122-00469.

    PMID: 40355349
  12. 12

    Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.

    Rajkumar SV, Bergsagel PL, Kumar S

    Hematology/oncology clinics of North America 2024; (38(2)):293-303 doi:10.1016/j.hoc.2023.12.001.

    PMID: 38158241
  13. 13

    Multiple Myeloma: Diagnosis and Treatment.

    Michels TC, Petersen KE

    American family physician 2017; (95(6)):373-383.

    PMID: 28318212
  14. 14

    Plasma cell myeloma in a 9-year-old male: Case report and literature review.

    Ronald K, Jacinta A, Umaru S

    Clinical case reports 2024; (12(4)):e8801 doi:10.1002/ccr3.8801.

    PMID: 38645602
  15. 15

    African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities.

    Pierre A, Williams TH

    Clinical journal of oncology nursing 2020; (24(4)):439-443 doi:10.1188/20.CJON.439-443.

    PMID: 32678364
  16. 16

    Biological determinants of health disparities in multiple myeloma.

    Smith CJ, Ambs S, Landgren O

    Blood cancer journal 2018; (8(9)):85 doi:10.1038/s41408-018-0118-z.

    PMID: 30190459
  17. 17

    Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.

    Pulte D, Jansen L, Castro FA, et al.

    British journal of haematology 2015; (171(2)):189-196 doi:10.1111/bjh.13537.

    PMID: 26123295
  18. 18

    Mortality trends in multiple myeloma after the introduction of novel therapies in the United States.

    Binder M, Nandakumar B, Rajkumar SV, et al.

    Leukemia 2022; (36(3)):801-808 doi:10.1038/s41375-021-01453-5.

    PMID: 34702976
  19. 19

    New Drugs in Multiple Myeloma.

    Kunacheewa C, Orlowski RZ

    Annual review of medicine 2019; (70()):521-547 doi:10.1146/annurev-med-112017-091045.

    PMID: 30691369
  20. 20

    The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma.

    Chakrabarti R, Siegel D, Biran N

    Clinical lymphoma, myeloma & leukemia 2025; (25(2)):96-108 doi:10.1016/j.clml.2024.08.004.

    PMID: 39261126

This guide provides an overview of Multiple Myeloma stages and symptoms for educational purposes. Always consult your hematologist or oncologist for specific diagnosis, prognosis, and treatment advice.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.